


Evoq Technologies Appoints Benjamin A. Bakall, MD, PhD as Scientific Advisor and Principal Investigator

LAS VEGAS, NV, UNITED STATES, October 18, 2025 /EINPresswire.com/ --Evog Technologies today announced the appointment of Benjamin A. Bakall, MD, PhD as a Scientific Advisor and Principal Investigator for upcoming clinical studies with the Twilight™ Dark Adaptometer. Dr. Bakall is a practicing retina specialist at Associated Retina Consultants in Phoenix, Arizona, and serves as Assistant Clinical Professor of Ophthalmology at the University of Arizona College of Medicine -Phoenix.

Dr. Bakall is internationally recognized for his contributions in inherited retinal disease and functional diagnostics. He is founder of the Retina Research Foundation of America and a member of leading professional organizations including the American Society of Retina Specialists (ASRS) and ARVO. His research includes widely cited work on gene therapy and emerging functional endpoints in retinal disease.

In his new role with Evoq, Dr. Bakall will guide the company's function-first





Evoq Technologies

diagnostic pipeline and lead real-world validation of the Twilight Dark Adaptometer, focusing on its sensitivity and specificity in detecting early retinal dysfunction.

About Evog Technologies

Evoq Technologies is a privately held corporation based in Henderson, Nevada. It is composed of an experienced team of scientists, engineers, clinicians, and seasoned business professionals with a track record of bringing innovative medical devices to market.



Dr. Bakall's expertise makes him a valuable addition to Evoq. His leadership in clinical studies ensures the Twilight Dark Adaptometer sets the standard for functional testing in everyday practice."

Daniel Lindgren, Co-Founder & Chief Executive Officer of Evoq Technologies

With a lineage that includes Xenotec and OcuScience, Evoq continues the mission of improving technology for doctors and scientists worldwide. Evoq develops and delivers high-quality diagnostic devices and platforms to advance the early detection of blindness, low vision, and neurological diseases. The company's SightGard™ platform integrates functional testing into routine care, empowering providers to detect retinal dysfunction earlier than ever before.

Daniel Lindgren
Evoq Technlogies
+1 816-529-5712
email us here
Visit us on social media:
LinkedIn
Facebook

This press release can be viewed online at: https://www.einpresswire.com/article/859261741

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.